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ABSTRACT
Background and Objectives: Alvimopan, a peripherally
acting mu-opioid receptor antagonist, decreased time to
gastrointestinal recovery and hospital length of stay in
open bowel resection patients in Phase 3 trials. However,
the benefit in laparoscopic colectomy patients remains
unclear.
Methods: A retrospective case series review was per-
formed to study addition of alvimopan to a well-estab-
lished standard perioperative recovery pathway for elec-
tive laparoscopic colectomy. The main outcome measures
were length of stay and incidence of charted postopera-
tive ileus. Wilcoxon and chi-square tests were used to
calculate P values for length of stay and postoperative
ileus endpoints, respectively.
Results: Demographic/baseline characteristics from the
101 alvimopan and 64 pre-alvimopan control patients
were generally comparable. Mean length of stay in the
alvimopan group was 1.55 days shorter (alvimopan,
2.810.95 days; control, 4.362.4 days; P.0001). The
proportion of patients with postoperative ileus was lower
in the alvimopan group (alvimopan, 2%; control, 20%;
P.0001).
Conclusion: In this case series, addition of alvimopan to
a standard perioperative recovery pathway decreased
length of stay and incidence of postoperative ileus for
elective uncomplicated laparoscopic colectomy. The im-
provement in the mean length of stay for patients who
receive alvimopan is a step forward in achieving a fast-
track surgery model for elective laparoscopic colectomies.
Key Words: Alvimopan, Colectomy, Laparoscopic, Path-
way.
INTRODUCTION
In addition to surgical technique, current surgical therapy
is placing emphasis on perioperative multidisciplinary
modalities to improve overall patient outcomes. One such
outcome variable, the length of stay after abdominal sur-
gery is decreasing. Many patients are experiencing earlier
gastrointestinal (GI) recovery and shorter postoperative
length of stay (LOS) due to advances in laparoscopy,
anesthesia, and implementation of perioperative recovery
pathways.1–5
Delayed GI recovery is the most common reason for
prolonged LOS after abdominal surgery and has multiple
negative effects including nausea, vomiting, inability to
tolerate diet progression, abdominal distension, and pa-
tient discomfort.6–9 Nausea and vomiting may lead to
aspiration and pneumonia, and delayed oral intake may
put a patient at higher risk for malnutrition.10 Abdominal
distention may lead to decreased respiratory reserve,
wound complications, and increased narcotic use leading
to further delay in return of bowel function and worsening
postoperative outcomes.10 Hospital costs are increased
because of prolonged stay and recruitment of resources to
manage delayed GI recovery and include radiologic im-
ages, parenteral nutrition, and laboratory tests.7,11,12 Fur-
thermore, prolonged hospital stay may also increase a
patient’s exposure to hospital-acquired pathogens and
illnesses.13,14
Gastrointestinal recovery after abdominal surgery is de-
pendent on many variables, including neurologic, inflam-
matory, and pharmacologic factors.15–18 Therefore, it
stands to reason that it would be beneficial to implement
a multimodal approach to accelerating GI recovery,
thereby shortening LOS after surgery. Accordingly, multi-
ple protocols to reduce the duration of postoperative ileus
(POI) have been proposed, with varied success.2–5,14,19
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SCIENTIFIC PAPERThese include various pre-, intra-, and postoperative com-
ponents in a variety of combinations and permutations.
However, despite the research demonstrating that path-
way use can accelerate GI recovery and decrease LOS, a
recent survey found that approximately 30% of physicians
who perform colectomies reside at a hospital with a peri-
operative care protocol for elective bowel resection that
include components to accelerate GI recovery.20
In May 2008, alvimopan (Entereg, Adolor, Exton, PA) a
peripherally acting -opioid receptor antagonist, received
FDA approval for the acceleration of time to upper and
lower GI recovery after partial large or small bowel resec-
tion with primary anastomosis.21,22 Alvimopan has been
shown in multiple studies to accelerate gastrointestinal
recovery after laparotomy.23–29 Across Phase 3 trials, in
comparison with placebo, alvimopan accelerated GI re-
covery by 11 hours to 26 hours and decreased postoper-
ative LOS by 0.3 day to 1.3 days after partial bowel resec-
tion.30 Patients who received alvimopan also had reduced
POI-related morbidity compared with those who received
placebo.30,31 In these trials, all patients (both those in the
alvimopan and placebo arms) were managed with a stan-
dardized postoperative care pathway that included re-
moval of the nasogastric tube by postoperative day 1,
early ambulation, and early advancement of diet.30
Because patients in the alvimopan clinical trials under-
went open colectomy, the benefit of using alvimopan in
patients undergoing laparoscopic colectomy is still un-
clear. However, a recent observational trial in laparo-
scopic bowel resection patients revealed that these pa-
tients can still experience POI-related morbidity after
laparoscopic surgery and that there is room for improve-
ment for GI recovery and time to discharge after laparo-
scopic bowel resection.32 Indeed, some recently pub-
lished single-institution/system studies have indicated a
potential benefit for alvimopan in patients undergoing
laparoscopic bowel resection.33,34 Therefore, based on the
drug’s mode of action, we propose that in patients for
whom opioid-based analgesia was used, alvimopan may
help accelerate patient GI recovery; thereby shortening
their hospital stay. We designed a retrospective chart re-
view to study the effect of adding alvimopan to a standard
perioperative recovery pathway used for elective laparo-
scopic partial colectomies.
MATERIALS AND METHODS
An institutional review board-approved, retrospective
chart review at one community hospital from July 2007
through January 2010 was conducted. Laparoscopic par-
tial colectomies performed over a period of 15 months
before and 15 months after the introduction of alvimopan
to the practice in November 2008 were retrospectively
studied in a community based colorectal surgery practice
of 2 colorectal surgeons.
Inclusion criteria for this study consisted of patients who
underwent a segmental colectomy with primary anasto-
mosis from July 2007 to January 2010. Exclusion criteria
included, emergent cases, conversion from laparoscopic
to open surgery, patients admitted to the hospital before
their day of surgery, concomitant surgical procedures (re-
sections to organs other than bowel), multiple anastomo-
ses, total colon resection, subtotal colon resection, oper-
ations for motility disorders or rectal prolapse, creation or
reversal of stomas, and in-patient perioperative complica-
tions that extended hospital stay except for POI (ie, other
operative or cardiopulmonary complications, urinary tract
infections, and others).
Consecutive patients who met the inclusion and exclusion
criteria listed above and who would have been candidates to
receive alvimopan (based on their preoperative opioid use)
in the 15-month period before drug introduction to the prac-
tice (controls) were compared with patients who received
alvimopan after it was introduced to the practice. To further
identify the patients who would have been candidates for
alvimopan based on their preoperative opioid use, the pa-
tient’s medication lists were reviewed and patients were
included in the control group arm only if they had not taken
narcotics in the 5 days prior to their operation.
A standardized perioperative care pathway for laparo-
scopic colectomy was used for all patients in this study.
Patients received intravenous patient controlled analgesia
(PCA) using morphine or hydromorphone (Dilaudid, Pur-
due Pharma, Canada) with scheduled intravenous ketoro-
lac for 24 hours postoperatively. On postoperative day 1,
the PCA was stopped and oral pain medication was
started (hydrocodone or equivalent). Pain was controlled
with oral pain medication, and all underlying medical
conditions were addressed. No patients received nasogas-
tric tubes. Sips of clear liquids began on postoperative day
0 (day of surgery). Additionally, on postoperative day 1, a
clear liquid diet was started and if tolerated, advanced to
full liquids the same day. On postoperative day 2, patients
were advanced to a soft diet as tolerated, regardless of
evidence of bowel sounds or return of bowel function,
provided the patient did not exhibit signs of worsening
distention or increased abdominal pain. Typically, pa-
tients were then discharged on a soft diet for 5 days
postoperatively. Discharge criteria included all of the fol-
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24 hours, tolerating a soft diet, passage of flatus or bowel
movement. Beginning in November of 2008, alvimopan
was added to the perioperative pathway and was used per
the label guidelines (once preoperatively, twice daily
postoperatively for up to 15 in-hospital doses).22
The primary outcome measures were LOS and POI, both of
which were collected by review of patient charts. Length of
stay was defined as the number of calendar days from day of
surgery to the day the patient physically left the hospital,
regardless of return to home or a rehabilitation facility. Post-
operative ileus, based on our group’s clinical experience, is
considered as a delay of return to bowel function more than
36 to 48 hours postoperatively that could not be attributed to
an organic cause (such as dehydration and electrolyte im-
balance), usually accompanied by abdominal distention and
nausea. The POI diagnosis was made by the surgeon at the
time of the hospital stay and was recorded in the discharge
summary. In our study, a patient was classified as having
experienced POI only if the diagnosis of POI was present in
the discharge summary. Thirty-day readmission and mortal-
ity data were also collected.
Wilcoxon tests were used to calculate P values for the
comparison of means (LOS, age, body mass index [BMI],
American Society of Anesthesiologists [ASA] score), and
chi-square tests were used to calculate P values for the
comparison of proportions (POI, sex, proportion of hand-
assist surgeries, indication for surgery, surgery type). Be-
cause the LOS data were not normally distributed and
right skewed, quasi-Poisson models were used to model
the LOS data; log number of days of LOS were used in the
model. Logistic regression was used to estimate the odds
ratios for the various coefficients. Logistic regression mod-
els were used to model the POI data.
RESULTS
In this study, 165 laparoscopic partial colectomies were
identified as eligible for inclusion in this study. The mean
age of patients was 62 years, the most common indication
for surgery was neoplasm, and the most common opera-
tion type was laparoscopic sigmoid colectomy (Table 1).
In the control and alvimopan groups, 14% and 10% of
laparoscopic surgeries, respectively, were hand-assisted.
The proportion of patients who underwent hand-assisted
laparoscopic surgery was not significantly different be-
tween groups, and the results for LOS were similar to
those observed for the full dataset when these patients
were excluded from the analysis.
Overall, the mean length of stay in the alvimopan group
was 1.55 days shorter than in the control group (alvimo-
pan, 2.81  0.95 days; control, 4.36  2.4 days; P.0001;
Figure 1). The LOS was reduced by approximately 1 day
to 2.5 days in the alvimopan group compared with control
in the 3 most common types of surgeries. A higher pro-
portion of patients in the alvimopan group were dis-
charged on Days 2 and 3 compared with patients in the
control group (Figure 2). Moreover, the outliers for
length of stay were significantly shorter for the alvimopan
group (1 day to 6 days) compared with the range for the
control group (2 days to 16 days). The 2 patients with the
longest LOS in the control group both had a diagnosis of
POI. Results of the Poisson model for LOS revealed that
alvimopan treatment significantly reduced LOS after ad-
justing for age, sex, BMI, ASA score, operative time, pres-
ence of POI, indication for surgery, surgery type, and
hand-assistance (P.001). In addition, the presence of
POI significantly increased LOS after adjusting for age,
sex, BMI, ASA score, operative time, indication for sur-
gery, surgery type, and hand assistance (P.001).
Postoperative ileus was noted in 2 of the patients (2%) in
the alvimopan group and 13 patients (20%) in the control
group (P.001). Results of the logistic regression model
revealed that LOS (P.003) and operative time (P.025)
were significantly associated with the presence of POI
after adjusting for age, sex, BMI, ASA score, and hand
assistance. Because some indications for surgery (Crohn’s
disease, appendicitis, A-V malformation) and surgery
types (left colectomy, transverse colectomy) were associ-
ated with low incidences of POI and the standard error of
estimates were very large because of small Ns, they were
not included in the model. However, a Fisher’s exact test
revealed that there was an association of surgery type
(P.021) but not indication for surgery with POI
(P.348). The surgery type with the largest proportion of
patients with POI (24%) was laparoscopic low anterior
resection.
Five patients (5.0%) in the alvimopan group and 3 patients
(4.7%) in the control group were readmitted 30 days after
surgery. In the alvimopan group, patients were readmitted
because of pneumonia (1 patient), wound infection (1
patient), Clostridium difficile colitis (1 patient), and anas-
tomotic leak (2 patients, 1 of which required reoperation).
In the control group, patients were readmitted because of
anemia and dehydration (1 patient), pulmonary embolus
(1 patient), and wound infection (1 patient). No patients in
either group died in the 30 days after surgery.
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A renewed interest in the prophylaxis and management of
POI has emerged in the past 3 years with the introduction of
a new class of drugs that can mitigate the negative effects of
opioids on the GI tract after surgery as well as new research
on perioperative care pathways that can accelerate GI recov-
ery and shorten hospital LOS.
2,3,9,19–21,35–37
Our group follows a standardized perioperative care path-
way for laparoscopic colectomy. Our pathway includes pre-
operative patient counseling to manage patient expectations,
the judicial use of early postoperative feeding, and a switch
from IV-PCA to oral opioids on postoperative day 1. These
pathway components, in addition to the use of minimally
invasive surgical technique, help our practice to minimize
the expected delay in GI recovery after colectomy.
This study of the effect of adding alvimopan to a stan-
dardized perioperative care pathway for laparoscopic co-
lectomy in a clinical practice setting has a number of
strengths. The reasonably robust sample includes data
from a homogenous group of patients as evidenced by the
generally comparable baseline demographics and surgical
characteristics. Moreover, the standardized pathway (which
was in effect since the beginning of 2007), perioperative
care modality, major equipment, and objective hospital
discharge criteria remained unchanged throughout the
duration of the study. Finally, the 2 operating surgeons
contributing data to this study have been in practice for
over 2 decades and performing laparoscopic colectomies
for more than a decade with consistent case loads. There-
fore, the decreased LOS observed in the alvimopan group
cannot likely be attributed to a surgeon learning curve
over time.
Like many evaluations of “real world” outcomes associ-
ated with drug use, this study has limitations. This was a
retrospective and un-blinded study. Data were from 2
Table 1.
Baseline Patient Demographics and Surgical Characteristics
Control Group (n64) Alvimopan Group (n101)
Female, n (%) 33 (52) 72 (61)
Mean age  SD 62.914.2 61.914.5
BMI  SD 27.74.65 28.37.8
ASA score  SD 2.40.50 2.40.48
Mean operation duration, minutes  SD 17329 15426
a
Primary indication for operation, n (%)
Neoplasm 44 (69) 6 (60)
Diverticulitis 19 (30) 38 (37)
Crohn’s disease 0 2 (2)
Appendicitis 0 1 (1)
A-V malformation 1 (1) 0
Operation type, n (%)
Laparoscopic sigmoid colectomy 26 (41) 41 (40)
Laparoscopic low anterior resection 19 (30) 35 (35)
Laparoscopic right colectomy 17 (27) 20 (20)
Laparoscopic left colectomy 1 (1) 3 (3)
Laparoscopic transverse colectomy 1 (1) 1 (1)
Operative technique, n (%)
Straight laparoscopy 55 (86) 91 (90)
Hand-assisted laparoscopy
b 9 (14) 10 (10)
Abbreviations: ASAAmerican Society of Anesthesiologists; A-Varteriovenous; BMIbody mass index; SDstandard deviation.
aP.001 based on a Wilcoxon test;
b Surgeries were considered hand-assisted if a hand gel port was used at any time during the
operation.
JSLS (2011)15:492–498 495surgeons in 1 practice and included patients with uncom-
plicated, elective laparoscopic colectomies only, which
may limit the generalization of the results. However, we
feel that our pathway and perioperative care modality are
common to many surgical practices. Patients were not
matched in our study other than based on the inclusion/
exclusion criteria and presurgery opioid use. Therefore, it
is possible that, although we are reasonably confident that
similar groups are being compared, there may be some
factors that we did not investigate that could influence
LOS and POI in addition to alvimopan use. However, for
the baseline criteria that were collected in this study,
including body mass index and American Society of An-
esthesiologists scores which may be considered as de-
faults for baseline comorbidity/risk, patients appear simi-
lar. Data for narcotic doses and use was not able to be
drawn from patient charts; however, perioperative care
practices remained unchanged for the duration of this
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Figure 1. Mean hospital length of stay overall and by operation type.
Note: The bars represent the standard deviation associated with each mean. The 3 most common operation types only are graphed.
Other operation types included in the overall category were left (n4) and transverse colectomy (n2).
aP.001 based on a Wilcoxon test;
bP.05 based on a Wilcoxon test.
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mained relatively similar in both cohorts; our pain man-
agement protocol (described in the methods) also re-
mained unchanged. Hospital discharge can be influenced
by factors in addition to GI recovery such as social support
and placement factors. Nevertheless, these factors would
presumably be similar in both cohorts in our study. In
addition, because a patient was only classified as experi-
encing POI if the diagnosis of POI was recorded in the
chart during the patient’s hospitalization, the rate of POI
could be underestimated if patients had symptoms of an
ileus but no diagnosis in the chart. Furthermore, the op-
erative time in the control group was approximately 20
minutes longer than the operative time in the alvimopan
group. Although this is statistically significant, 20 minutes
may or may not be clinically meaningful with respect to
increasing risk for POI. Indeed, a recent retrospective
database review of over 400 segmental laparoscopic co-
lectomies found that increasing operative time did not
adversely affect perioperative outcomes, including LOS.38
Finally, hospital cost data were not collected in our study.
However, in a recently published study33 of alvimopan
use in laparoscopic bowel resection at a regional medical
center, a 1.1 day reduction of LOS was associated with a
hospital cost savings of $1,368 (this included alvimopan
costs). Therefore, it is likely that, based on a day and a half
reduction in LOS, cost savings will be realized at our
institution as well. Despite these study limitations, we feel
this study provides meaningful data regarding alvimopan
use in elective laparoscopic partial colectomy patients.
Based on the positive results of this study we have mod-
ified our preoperative patient counseling. Previously, we
informed all patients undergoing laparoscopic colectomy
that the postoperative LOS, barring any complication,
could be expected to be between 3 to 5 days. This LOS
was corroborated by our results of 4.4 days in the control
group of this study. However, based on the mean LOS in
the alvimopan group of our study, we have recently short-
ened the expected LOS for patients to 2 to 4 days. Fur-
thermore, the addition of alvimopan to our pathway ap-
pears to yield a more consistent response with respect to
our expected LOS for uncomplicated laparoscopic colec-
tomies; fewer patients remain in the hospital beyond 4
days (ie, fewer outliers).
CONCLUSION
The addition to alvimopan to a standardized perioperative
care pathway for elective laparoscopic partial colectomies
decreased the mean LOS by 1.5 days in our practice. We
encourage further studies in other clinical practices and in
randomized, controlled trials to corroborate our results.
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